Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial)
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Spartalizumab (Primary) ; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ElevatION:NSCLC-101
- Sponsors Novartis Pharmaceuticals
- 23 Oct 2018 Planned End Date changed from 6 Nov 2019 to 15 Feb 2022.
- 23 Oct 2018 Planned primary completion date changed from 6 Nov 2019 to 15 Feb 2022.
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.